EDITOR -We re ad w ith great inte re st the public ation from Pé re z-Arellano and colle ague s. 1 The aim of this study w as to evaluate the p artic ipation of PAF in ex trinsic allergic alve olitis. We w ould like to bring to your atte ntion the fac t that w e p ublishe d a similar study a few years ago.
EDITOR -We re ad w ith great inte re st the public ation from Pé re z-Arellano and colle ague s. 1 The aim of this study w as to evaluate the p artic ipation of PAF in ex trinsic allergic alve olitis. We w ould like to bring to your atte ntion the fac t that w e p ublishe d a similar study a few years ago. 2 Both studies show striking me thodological similarities, namely the use of the same antigen to induce EAA and the same PAF antagonist. How e ver, w e reported a de creased total BAL cell counts in BN 52021 treated animals in contrast to the results as de scribe d by Pé rez-Arellano e t a l. We acknow ledge that the y looke d at more parame te rs than w e did, but it w ould have bee n fair just to me ntion our pre vious public ation in the introduc tion and disc uss discrepanc ie s betw e en their and our results. Considering the easy acc ess to published materials w ith database s such as PubMe d, w e que stion if such an omission w as inte ntional, espec ially w hen both studie s reach a similar conclusion.
Reply to G. Tremblay

J.L. Perez-Arellano
De partment of Medical Scie nce and Surgery, University of Las Palmas de Gran Canaria, Spain EDITOR -We regre t that Dr Tre mblay's w ork w as not me ntioned in our paper. A more thorough se arching of the database might have found his pape r, but at the time w e w ere unaw are of its ex iste nce . For this w e w ould ask you to send our apologie s to Dr Tremblay.
How ever , w e disagre e w ith a number of points made by Dr Tremblay, namely:
(a) We do not think that the re are 'striking me thodologic al similaritie s' be tw ee n both pape rs. Briefly, w e used an ex perimental mode l previously de scri- Furthe rmore , the y used an intrana sal route for administration of antige n w hereas in our w ork w e used intratracheal administration. More over, the protocol of administration of the antige n and BN 52021 is very diffe re nt in both papers. The se differences could probably ex plain the disc repancie s obse rved in the results obtained for total and differe ntial c ounts. (b) Concerning the c riticism about the use of the 'same antigen', w e should point out that Fa e n ia re c tivirg u la has been used for a long time in ex pe rimental mode ls of ex trinsic allergic alve olitis by many groups. 1 -3 Spec ifically, w e use the protocol of Schuyle r and Crooks 4 as indicated in our paper. Indeed, as me ntioned in our paper (ref.
17), one of us (Prof. J.M. Lopez Novoa) has use d BN 52021 (provided by Dr P. Braquet) prior to 1993 (the date of publication of Dr Tre mblay's paper). We are the re fore ve ry surprised that Dr Tremblay see s fit to draw attention to our use of this antigen w he n it is so w ide ly used by othe rs, and strongly refute the implication in his final se nte nce that w e inte ntionally omitted to cite his w ork. (c) The me thods used for the e valuation of the role of PAF in the pathogenesis of EAA is very different in both papers. The ir results include tw o main aspec ts: the number and type of ce lls rec overed in BAL, and the production of eic osanoids by alveolar macrophage s. In our w ork w e evaluate d se veral parameters of pare nchymal lung disease (not only alve olitis) and w e measure d PAF dire ctly. So, w ith the ex cep tion of BAL lavage (a technique used in all pap ers that investigate the pathoge nesis of interstitial lung disease) the rationale of the w ork is totally diffe rent.
In conclusion, w hile w e rec ognize the omission of their very intere sting paper from our p ape r, w e strongly deny that this w as in any w ay deliberate.
